CME / CE
TARGET AUDIENCE
These activities are intended for physicians, physician assistants, pharmacists, registered nurses, nurse practitioners,
and registered dietitians with an interest in lipid management.
LEARNING OBJECTIVES
Scientific Sessions
At the conclusion of this activity, Registered Nurses and Nurse Practitioners should be able to provide
appropriate care and counsel for patients and their families.
At the conclusion of this activity, all participants should be able to:
Masters Summit on Emerging LDL Therapies
- Review the pathogenesis of atherosclerotic plaque development and progression.
- Apply insight from human genetics to identify novel therapeutic targets that may prevent atherosclerotic cardiovascular disease.
- Identify the mechanisms of action, efficacy and safety of novel LDL-targeting therapies and their potential roles in reducing risk
in patients with CVD.
Keynote Address & Opening Session
- Critically appraise recent clinical trials and apply important research to daily clinical practice.
- Prevention & Public Health-Racial & Ethnic Differences
- Discuss epidemiology and risk profiles for dyslipidemia in minority ethnic groups in the United States;
- Evaluate data on dyslipidemia in minority populations, and recommend how screening and management practices may be modified in
response to these data.
Gender Issues in Coronary Artery Disease
- Identify how pathophysiological differences between the sexes influences risk factors, presentations, and outcomes associated with CVD;
- Describe how sex hormones and hormone replacement therapies impact the development of CVD in men and women.
Optimizing Adherence-Overcoming Special Challenges: The Statin USAGE Survey
- Correctly indicate the frequency and secondary causes of statin intolerance and treatment options for statin-intolerant patients;
- Identify contributing factors and implications of nonadherence to lipid-lowering therapies in light of recent findings.
Debate: Is it EPA or EPA & DHA? Only Your Neighborhood Lipidologist Knows For Sure
- Describe the pharmacologic differences within the omega-3 fatty acid class, including alpha-linolenic acid, eicosapentaenoic acid,
and docosahexaenoic acid;
- Interpret evidence from recent clinical trials relating to the efficacy of omega-3 fatty acids in the management of dyslipidemia.
Atherosclerotic Plaque: Imaging and Dynamics
- Recognize the concepts of treatment induced favorable atheroma changes including: slowing atherosclerotic
progression, enhancing lipid core regression, stabilizing vulnerable plaque and 'quiescent progression;'
- Analyze the role of contemporary diagnostic tools for the detection of unstable plaque.
Insulin Resistance, Diabetes and Its Complications
- Develop a systematic treatment plan for managing lipid abnormalities in patients with cardiometabolic risk factors;
- Describe the effect of lipoprotein-related mechanisms and lipid medications on the vascular complications of diabetes.
Special Session: Sugar, Salt and Everything that Peppers the Landscape
- Describe the association of specific dietary patterns such as increased sodium and sugar intake, and the
increased risk for cardiovascular disease associated morbidity and mortality;
- Recognize the importance of lifestyle modification in the reduction of cardiometabolic risk and implement
strategies for encouraging appropriate changes in patients.
Nutrition and Lifestyle Counseling Workshop: New Strategies and Technologies for Clinical Practice
- Apply new strategies for implementing dietary recommendations for lipid management;
- Employ effective counseling techniques and motivational interviewing skills to facilitate adherence to lifestyle recommendations;
- Review information technologies for lifestyle and dietary behavior changes.
Lipid and Cardiometabolic Risk Reduction Programs: Strategies for Successful Start-up and Operations.
- Recognize and address the key lipid and cardiometabolic risk reduction program operational issues and efficient models of care;
- Identify and apply effective treatment plan development, federal regulations, clinical performance reporting measures,
and referral strategies to ensure clinical and operational success.
- Principles of Evidence-based Practice: Intensive Workshop
- Describe the epidemiology and statistical evidence related to cardiovascular disease risk in the context of evidenced-based medicine;
- Critically appraise current clinical trials and methods to apply evidence-based medicine into daily clinical practice;
- Apply evidence-based medicine strategies for the prevention, screening, and treatment of atherosclerosis risk factors and their
co-morbidities to clinical practice.
Lipid Academy™
At the conclusion of this activity, Registered Nurses and Nurse Practitioners should be able to provide
appropriate care and counsel for patients and their families.
At the conclusion of this activity, participants should be able to:
- Identify the functions and source of cholesterol and triglycerides, and describe the role of lipoproteins in atherosclerosis;
- Identify primary and secondary causes of dyslipidemia;
- Outline current guidelines on the diagnosis, management and treatment of patients with dyslipidemia;
- Assess the impact of diet, exercise and behavior modifications on cardiovascular risk and risk factors;
- Outline the principles of pharmacological management of dyslipidemia, including the effect of each agent on atherosclerotic disease,
serum lipids, and lipoprotein metabolism;
- Describe aggressive therapies for the management of complex lipid disorders, metabolic syndrome and residual risk;
- Describe cardiometabolic risk factors and their impact on cardiovascular health;
- Critically appraise landmark clinical trials and apply important research to daily clinical practice;
- Evaluate current and novel advanced lipid tests and biomarkers for atherosclerosis and their potential applications for
CV risk detection and management, as well their limitations.
Masters in Lipidology™
At the conclusion of this activity, Registered Nurses and Nurse Practitioners should be able to provide appropriate care and
counsel for patients and their families.
At the conclusion of this activity, participants should be able to:
- Discuss lipoprotein metabolism, including the role of the vascular system in the pathogenesis of atherosclerosis;
- Explain the role genetic disorders play in lipoprotein metabolism;
- Critically appraise landmark clinical trials and apply important research to daily clinical practice;
- Manage dyslipidemias according to patient profile;
- Assess traditional and emerging markers for atherosclerotic cardiovascular;
- Critique the role of drug therapies, nutrition, and therapeutic life style management of dyslipidemias;
- Manage Cardiometabolic risk factors of the metabolic syndrome;
- Describe aggressive therapies for the management of complex lipid disorders, metabolic syndrome and residual risk.
The Translation of HDL Science Master Class
At the conclusion of this activity, Registered Nurses and Nurse Practitioners should be able to provide appropriate care
and counsel for patients and their families.
At the conclusion of this activity, participants should be able to:
- Evaluate the role of HDL-C in reducing cardiovascular events and rates of atherosclerotic disease progression;
- Describe the mechanisms involved in the production, metabolism, and functionality of HDL including how they relate to atherogenesis;
- Identify the genetic causes of low and high serum HDL-C including the clinical and research implications of these genetic disorders;
- Review the role of HDL subfractions and apolipoproteins as risk factors;
- Outline the various HDL receptors and metabolic pathways and their pleiotropic effects;
- Compare the relative effectiveness of existing treatments to raise HDL and reduce CVD risk;
- Discuss recent evidence regarding the utility of HDL as a target for CVD risk modification including the clinical
implications for patient management.
ACCREDITATION
Physicians
The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing
medical education for physicians. This activity has been planned and implemented in accordance with the Essential Areas and policies
of the Accreditation Council for Continuing Medical Education. The National Lipid Association designates these live activities:
Scientific Sessions for a maximum of 17.5 AMA PRA Category 1 Credit(s)™ Lipid AcademyTM for a maximum of 11.5 AMA PRA Category 1
Credit(s)™; Masters in LipidologyTM for a maximum of 16 AMA PRA Category 1 Credit(s)™; and The Translation of HDL Science Master
Class for a maximum of 10.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Physician Assistants
NCCPA accepts AMA PRA Category I Credit™ from
organizations accredited by ACCME.
American Academy of Family Physicians
This Live activity, Extending the Reach and Inclusiveness of Lipidology, with a beginning date of May 31, 2012, has been reviewed and is acceptable for up to 17.25
Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Approval for AAFP CME credit does not imply authorization to use the AAFP logo on CME activity materials or to use AAFP's name in any association with the activity
other than the credit statement.
AMA/AAFP Equivalency:
AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit™ toward the AMA Physician's Recognition Award.
When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.
 CE Credit provided by Postgraduate Institute for Medicine
Pharmacists
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of
continuing pharmacy education.
Masters Summit on Emerging LDL Therapies
Universal Activity Number - 0809-9999-12-160-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 3.5 contact hour(s) (0.35 CEUs)
of the Accreditation Council for Pharmacy Education.
AIM-HIGH/Courage Keynote Address
Universal Activity Number - 0809-9999-12-161-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs)
of the Accreditation Council for Pharmacy Education.
Prevention and Public Health Session-Racial and Ethnic Differences
Universal Activity Number - 0809-9999-12-162-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) of
the Accreditation Council for Pharmacy Education.
Gender Issues in Coronary Artery Disease
Universal Activity Number - 0809-9999-12-163-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) of the
Accreditation Council for Pharmacy Education.
Optimizing Adherence-Overcoming Special Challenges: The Statin USAGE Survey
Universal Activity Number - 0809-9999-12-164-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the
Accreditation Council for Pharmacy Education.
Debate Session: Is it EPA or EPA & DHA? Only Your Neighborhood Lipidologist Knows For Sure
Universal Activity Number - 0809-9999-12-165-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the
Accreditation Council for Pharmacy Education.
Atherosclerotic Plaque Session
Universal Activity Number - 0809-9999-12-166-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs)
of the Accreditation Council for Pharmacy Education.
Metabolic Syndrome and Cardiometabolic Session
Universal Activity Number - 0809-9999-12-167-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of
the Accreditation Council for Pharmacy Education.
Special Session: Sugar, Salt and Everything that Peppers the Landscape
Universal Activity Number - 0809-9999-12-168-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hour(s) (0.2 CEUs) of
the Accreditation Council for Pharmacy Education.
Evidence-based Medicine
Universal Activity Number - 0809-9999-12-171-L01-P (Knowledge)
Postgraduate Institute for Medicine designates this continuing education activity for 3.0 contact hour(s)
(0.3 CEUs) of the Accreditation Council for Pharmacy Education.
Nutrition and Lifestyle Counseling
Universal Activity Number - 0809-9999-12-169-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 3 contact hour(s)
(0.3 CEUs) of the Accreditation Council for Pharmacy Education.
Lipid Clinic Operations and Development
Universal Activity Number - 0809-9999-12-170-L01-P (Application)
Postgraduate Institute for Medicine designates this continuing education activity for 3.0 contact hour(s)
(0.3 CEUs) of the Accreditation Council for Pharmacy Education.
Nursing
This educational activity for 17.1 contact hours is provided by Postgraduate Institute for Medicine.
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses
Credentialing Center's Commission on Accreditation.
Masters Summit on Emerging LDL Therapies - 3.5 contact hours; AIM-HIGH/Courage Keynote Address - 1.0 contact hours;
Prevention and Public Health Session-Racial and Ethnic Differences - 1.2 contact hours; Gender Issues in Coronary
Artery Disease - 1.2 contact hours; Optimizing Adherence-Overcoming Special Challenges: The Statin USAGE Survey- 1.0 contact hours;
Debate Session: Is it EPA or EPA & DHA? Only Your Neighborhood Lipidologist Knows For Sure- 1.5 contact hours; Atherosclerotic
Plaque Session- 1.2 contact hours; Metabolic Syndrome and Cardiometabolic Session- 1.5 contact hours; Special Session: Sugar,
Salt and Everything that Peppers the Landscape- 2.0 contact hours; Evidence-based Medicine- 3.0 contact hours; Nutrition and
Lifestyle Counseling- 3.0 contact hours; Lipid Clinic Operations and Development- 3.0 contact hours.
Dietitians
This program has been submitted for approval to the Commission on Dietetic Registration (CDR) for 17.25 CPEUs.
Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 3.5 (Masters Summit on Emerging LDL Therapies);
1.0 (AIM-HIGH/Courage Keynote Address); 1.25 (Prevention and Public Health Session-Racial and Ethnic Differences);
1.25 (Gender Issues in Coronary Artery Disease); 1.0 (Optimizing Adherence-Overcoming Special Challenges: The Statin USAGE Survey);
1.5 (Debate Session: Is it EPA or EPA & DHA? Only Your Neighborhood Lipidologist Knows For Sure); 1.25 (Atherosclerotic Plaque Session);
1.5 (Metabolic Syndrome and Cardiometabolic Session); 2.0 (Special Session: Sugar, Salt and Everything that Peppers the Landscape);
(Evidence-based Medicine); 3.0 (Nutrition and Lifestyle Counseling); 3.0 (Lipid Clinic Operations and Development) continuing
professional education units (CPEUs) for completion of this program/material.
Criteria for Success
Statements of credit will be awarded based on the participant's attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/ claimed credit form at www.lipid.org/cme.
Commercial Support
Full notification of commercial support will be provided in the activity syllabus.
|
